The Food & Drug Administration and the Centers for Medicare and Medicaid are opening up their plans for concurrent evaluations of pre-market, FDA-regulated medical products to public comment.
The two agencies are working to promote data-sharing between themselves and signed a memorandum of understanding over the proposed collaboration June 23. A partnership between FDA and Medicare could make the approval process for new drugs and devices more efficient. A 90-day public comment period on the possible collaboration begins tomorrow.
